Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis
about
Recent Treatments of Interstitial Lung Disease with Systemic SclerosisRedox regulation of T-cell function: from molecular mechanisms to significance in human health and diseaseImaging lung disease in systemic sclerosis.Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease.Interstitial lung disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design.Systemic sclerosis-dermatological aspects. Part 1: Pathogenesis, epidemiology, clinical findings.Reduced incidence of Crohn's disease in systemic sclerosis: a nationwide population study.Computer-Aided Tomographic Analysis of Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc). Correlation with Pulmonary Physiologic Tests and Patient-Centred Measures of Perceived Dyspnea and Functional Disability.Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study.Quantitative volumetric assessment of pulmonary involvement in patients with systemic sclerosis.The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis.Diagnosis and treatment of connective tissue disease-associated interstitial lung disease.Membrane diffusion- and capillary blood volume measurements are not useful as screening tools for pulmonary arterial hypertension in systemic sclerosis: a case control study.Update in diffuse parenchymal lung disease 2007.Prevalence of ocular manifestations in systemic sclerosis patientsCirculating biomarkers of interstitial lung disease in systemic sclerosis.Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung diseaseLong-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.Associations between Systemic Sclerosis and Thyroid Diseases.Assessment of fatigue and its relationships with disease-related parameters in patients with systemic sclerosis.Thalidomide has a therapeutic effect on interstitial lung fibrosis: evidence from in vitro and in vivo studies.Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease.
P2860
Q26773161-16366819-4BAA-44A3-8510-071AD093EBAAQ26824042-2148885B-4B76-4563-A7B6-C8AB472D91D6Q33754571-23E2C52B-ADD3-4609-9CEA-6EEBB6C77D6DQ33891119-84B17D0B-D6F3-4F5D-A6DF-593DBBAEC965Q33956830-68FBF459-851E-47E4-BB42-EBCB825CDDD6Q34027197-6DBB32FD-1F67-46A0-82C1-07790BF7E7EFQ34295337-78BCF19C-9A2E-49B2-8BE5-5FB7DD3A1450Q35775371-5579FC7F-0422-4836-9CAD-0B5465FD1599Q35941472-73251CC7-A719-49E0-B80E-9497D749CEC9Q36212638-B9BD1270-0642-476E-B73D-371B176B7987Q36642268-C09D5062-7ADB-40AF-B37D-BA78F4ADE2B8Q36645934-E50A2555-652D-4FC7-99DB-D7E13422775DQ36664408-C6406BA5-A568-4619-BF36-FF023A6A492CQ36956827-17E0A6BB-4C6F-44A6-8D2D-CEEFD67A9215Q37100706-B5BA9F55-4D14-4384-866E-884FECE7D829Q37517907-4CC2DE4D-08AF-4E19-994B-4C78E791EA19Q38044387-98908EAF-1649-418A-8CD5-B9E18686F5DFQ38649246-7B3DCC64-A5D5-4707-9AB4-B832E2B09ACBQ38880396-65480B01-3109-4123-A1B7-378601AF16B8Q42372554-AD901CCD-6524-4262-847A-4355D0FBF641Q44384767-A32A1E00-1735-4302-98B6-F93AE4421719Q45928620-AEE6F51D-433C-4026-B18F-8F9F7CE877E2Q47189018-48A7536E-3E6E-4994-BD17-3D0FABA62EE3
P2860
Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Scleroderma lung study (SLS): ...... sus diffuse systemic sclerosis
@ast
Scleroderma lung study (SLS): ...... sus diffuse systemic sclerosis
@en
type
label
Scleroderma lung study (SLS): ...... sus diffuse systemic sclerosis
@ast
Scleroderma lung study (SLS): ...... sus diffuse systemic sclerosis
@en
prefLabel
Scleroderma lung study (SLS): ...... sus diffuse systemic sclerosis
@ast
Scleroderma lung study (SLS): ...... sus diffuse systemic sclerosis
@en
P2093
P2860
P50
P356
P1476
Scleroderma lung study (SLS): ...... sus diffuse systemic sclerosis
@en
P2093
Daniel E Furst
Donald P Tashkin
James R Seibold
Kari Connelly
Marcy Bolster
Mark Metersky
Michael D Roth
Mildred Sterz
Philip J Clements
P2860
P304
P356
10.1136/ARD.2007.069518
P407
P577
2007-05-07T00:00:00Z